184896-92-2

Upstream product

• 28547-13-9 3-(methanesulfonamido)benzoic acid 
• 582-33-2 3-aminobenzoic acid ethyl ester 
• 93884-11-8 ethyl 3-(methylsulfonamido)benzoate 

Downstream Products

• 1357294-91-7 N-[3-(6,7-dimethoxy-3-n-butyl-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methanesulfonamide 
• 1357294-66-6 4,5-dimethoxy-N-n-butyl-2-{[3-((methylsulfonyl)amino)phenyl]carboxamido}benzamide 
• 119085-49-3 N-[2-Acetyl-4-(3,4-dimethoxy-phenyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl]-methanesulfonamide 
• 119085-48-2 N-[4-(3,4-Dimethoxy-phenyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl]-methanesulfonamide 
• 119085-50-6 N-[2-Acetyl-4-(3,4-dihydroxy-phenyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl]-methanesulfonamide 
• 119085-47-1 N-(3-{[2-(3,4-Dimethoxy-phenyl)-2-hydroxy-ethylamino]-methyl}-phenyl)-methanesulfonamide 

Relevant academic research and scientific papers

Cytotoxic potential of novel 6,7-dimethoxyquinazolines

Herein, we report the synthesis and cytotoxicity of a series of substituted 6,7-dimethoxyquinazoline derivatives. The cytotoxic activity of all synthesized compounds has been evaluated against HCT116p53+/+ and HCT116p53 -/- colon cancer cells and a HEY ovarian cancer cell line naturally resistant to cisplatin. Nine of the tested compounds showed significant cytotoxicity in all cell lines at 10 μM. The most promising derivative (7c) showed IC50values of 0.7 and 1.7 μM in the two colon cancer cell lines.

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds of formula (I) that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.

4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship

A series of 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives showed potent DA1 agonistic activities. We investigated the structure-activity relationship of the racemic compounds of this series. 4- (3,4-Dihydroxyphenyl)-7-metha